{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:14:36Z","timestamp":1774340076216,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint blockade (ICB) brings hope to many late-stage cancer patients yet its marker for response remains elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We developed a hypothesis that treatment-related adverse events (TrAEs) could predict objective response rate (ORR) to ICB. We plotted ORR against corresponding any and grade 3 to 5 (G3\u20135) TrAEs across a variety of cancer types by performing a meta-analysis using linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We identified 113 eligible studies encompassing 25 types of malignancies that were treated with ICB or ICB-based regimes. A significant linear correlation was observed for any and severe TrAEs, respectively. The correlation coefficient was 0.57 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.324) for any TrAE and 0.61 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.37) for G3\u20135 TrAE. For melanoma, the correlation coefficient was 0.81 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.57) for any TrAE and 0.65 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.42) for G3\u20135 TrAEs. For RCC, the correlation coefficient was 0.86 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.74) for any TrAE and 0.91 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.83) for G3\u20135 TrAE. For NSCLC, the correlation coefficient was 0.55 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.3) for any TrAE and 0.74 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.86) for G3\u20135 TrAE. For UC, the correlation coefficient was 0.47 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.68) for any TrAE and 0.27 (\n                      <jats:italic toggle=\"yes\">r<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a0.52) for G3\u20135 TrAE, yet the correlation was insignificant for severe AEs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings suggest that over half of ICB responses could be reflected by any adverse events and \u223c60% of responses could be reflected by severe AEs. Further validation is needed in individual trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000022153","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T02:05:17Z","timestamp":1599703517000},"page":"e22153","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade"],"prefix":"10.1097","volume":"99","author":[{"given":"Yanyun","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Anesthesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duoqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhidong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huashan Hospital, Fudan University, PR China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"R1-20251104","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"R2-20251104","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20251104","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20251104","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"R5-20251104","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"R6-20251104","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20251104","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line Nivolumab plus Ipilimumab vs Sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"(Pt 1)","key":"R9-20251104","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R10-20251104","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with Nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"R11-20251104","first-page":"2303","article-title":"Pembrolizumab for advanced urothelial carcinoma","volume":"376","author":"Guo","year":"2017","journal-title":"N Engl J Med"},{"key":"R12-20251104","article-title":"Treatment-related adverse events and response rate to immune checkpoint inhibition","author":"Li","year":"2019","journal-title":"J Int Med Res"},{"key":"R13-20251104","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20251104","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD013009","article-title":"Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol","author":"Syn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20251104","first-page":"CD011300","article-title":"Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent","volume":"12","author":"Zhu","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20251104","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"R17-20251104","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"R18-20251104","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"R19-20251104","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R20-20251104","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"R21-20251104","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with Nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"Oncologist"},{"key":"R22-20251104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"R23-20251104","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with Nivolumab: a prospective cohort study","volume":"12","author":"Teraoka","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R24-20251104","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center","volume":"6","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"(15_suppl)","key":"R25-20251104","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1200\/JCO.2018.36.15_suppl.6014","article-title":"Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy","volume":"36","author":"Foster","year":"2018","journal-title":"J Clin Oncol"},{"issue":"(15_suppl)","key":"R26-20251104","doi-asserted-by":"crossref","first-page":"e14087","DOI":"10.1200\/JCO.2019.37.15_suppl.e14087","article-title":"Association of immune-related adverse events with immune checkpoint inhibitor efficacy in pancancer","volume":"37","author":"Ou","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:01:36Z","timestamp":1762243296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000022153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":25,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000022153","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"2020-03-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}